Serimmune antibody analysis results
The Serimmune COVID-19 Study is a longitudinal research study conducted by the Serimmune company. The study uses the company's "Serum Epitope Repertoire Analysis (SERA) technology" to study antibody responses, especially in the context of COVID-19 vaccination and exposure.
The company pre-published[1] the technical details behind their platform.
The study returns research-grade results (not intended for diagnostic clinical use) to participants. As described in the study consent document, these results are not clinically validated and not meant to serve as a clinical assay. They are, nevertheless, interesting to look at!
The study is planned to last five years, with blood samples collected every six months. Samples are self-collected by participants using a home collection kit and sent by mail.
Project Infobox | |
---|---|
Self researcher(s) | User:Madprime, User:Sprague |
Related tools | |
Related topics | |
Builds on project(s) |
|
Has inspired | Projects (0) |
SARS-CoV-2 Antibody Analyses
Individual | Date | Report | Vaccination | Natural infection | Notes |
---|---|---|---|---|---|
User:Sprague | 2021-12-14 | File:RichardSpragueSerimmuneCOVID 20211214.pdf | Pfizer | No | Pfizer vaccine (two shots, no booster) |
User:Madprime | 2022-02-03 | File:TOEAIX 20220203.pdf | Moderna | No | Moderna vaccine (two shots, plus booster). |
User:Madprime | 2022-05-27 | File:TOEAIX 20220527.pdf | Moderna | Yes | Covid positive on 2022-05-01. |
User:Madprime | 2022-08-04 | File:TOEAIX 20220804.pdf | Moderna | Yes | No additional history. |
User:Igerg | 2022-04-13 | File:EXACZL 20220413.pdf | Moderna | No | Moderna vaccine (two shots, plus booster) - chronic spontaneous urticaria following booster |
User:EricJain | 2022-07-21 | File:EricJain-Serimmune-20220721.pdf | Pfizer | No | Report includes comparison to 2022-01-20. Vaccinations: 2021-04-21 (Pfizer), 2021-05-12 (Pfizer), 2021-12-08 (Pfizer). |
Other results
In addition to COVID-19 related antibody analyses, the study shares research analysis of antibodies related to infectious diseases (Lyme Disease, Ehrlichiosis, Anaplasmosis, Babesiosis, Chagas Disease) and autoimmune conditions (Celiac Disease).
Individual | Date | Report | Notes |
---|---|---|---|
User:Sprague | 2021-12-14 | File:RichardSpragueSerimmune 20211214.pdf | |
User:Madprime | 2022-02-03 | File:TOEAIX Expanded 20220203.pdf | No medical history related to these analyses. |
User:Igerg | 2022-04-13 | File:EXACZL Additional 20220413.pdf | Tested for Lyme several times, all negative |
User:Madprime | 2022-05-27 | File:TOEAIX Additional 20220527.pdf | |
User:Madprime | 2022-08-04 | File:TOEAIX Additional 20220804.pdf |
Linked content on this wiki
(The content in the table below is automatically created. See Template:Project Queries for details. If newly linked pages do not appear here, click on "More" and "Refresh".)
Project that build on this project |
---|
We talked about this project in the following meetings |
---|
2022-05-26 Self-Research Chat, 2022-06-02 Self-Research Chat, 2022-07-14 Self-Research Chat, 2022-09-15 Self-Research Chat, 2022-12-29 Self-Research Chat |
- ↑ High-resolution mapping and characterization of epitopes in COVID-19 patients Winston A. Haynes, Kathy Kamath, Joel Bozekowski, Elisabeth Baum-Jones, Melissa Campbell, Arnau Casanovas-Massana, Patrick S. Daugherty, Charles S. Dela Cruz, Abhilash Dhal, Shelli F. Farhadian, Lynn Fitzgibbons, John Fournier, Michael Jhatro, Gregory Jordan, Debra Kessler, Jon Klein, Carolina Lucas, Larry L. Luchsinger, Brian Martinez, Mary C. Muenker, Lauren Pischel, Jack Reifert, Jaymie R. Sawyer, Rebecca Waitz, Elsio A. Wunder Jr., Minlu Zhang, Yale IMPACT Team, Akiko Iwasaki, Albert I. Ko, John C. Shon medRxiv 2020.11.23.20235002; doi: https://doi.org/10.1101/2020.11.23.20235002